Fusion Pharm Stock Probability of Future Stock Price Finishing Under 1.0E-4
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion |
Fusion Pharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Fusion Pharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Fusion Pharm can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for 2 Billion - MSN |
Fusion Pharm Technical Analysis
Fusion Pharm's future price can be derived by breaking down and analyzing its technical indicators over time. Fusion Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Fusion Pharm. In general, you should focus on analyzing Fusion Stock price patterns and their correlations with different microeconomic environments and drivers.
Fusion Pharm Predictive Forecast Models
Fusion Pharm's time-series forecasting models is one of many Fusion Pharm's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Fusion Pharm's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Fusion Pharm
Checking the ongoing alerts about Fusion Pharm for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Fusion Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Fusion Pharm generated a negative expected return over the last 90 days | |
| Fusion Pharm has some characteristics of a very speculative penny stock | |
| Fusion Pharm has high likelihood to experience some financial distress in the next 2 years | |
| Fusion Pharm currently holds 1.2 K in liabilities. Fusion Pharm has a current ratio of 0.72, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Fusion Pharm's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 594.4 K. Net Loss for the year was (42.08 K) with profit before overhead, payroll, taxes, and interest of 34.19 K. | |
| Fusion Pharm has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: AstraZeneca Bets on New Cancer Treatments By Acquiring Fusion Pharmaceuticals for 2 Billion - MSN |
Check out Fusion Pharm Backtesting, Fusion Pharm Valuation, Fusion Pharm Correlation, Fusion Pharm Hype Analysis, Fusion Pharm Volatility, Fusion Pharm History as well as Fusion Pharm Performance. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Consumer Staples Distribution & Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.